Asunaprevir

Background: Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.

Indication: Asunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis C in adult patients with hepatitis C virus genotypes 1 or 4 and compensated liver cirrhosis.

Hepatitis C is a liver disease caused by the hepatitis C virus. The chronic state of this condition accounts for 60-80% of the cases from which the risk of cirrhosis of the liver within 20 years is of around 15-30%. The genotype 1 is the most common type of hepatitis C in the United States and the most difficult to treat.

Associated Conditions: Chronic Hepatitis C Genotype 1, Genotype 4 Chronic Hepatitis C

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Phase 3

Completed

Interventions: Drug: Asunaprevir
Drug: Daclatasvir
Drug: Peg-interferon Alfa-2a
Drug: Ribavirin

Locations: 🇺🇸
University Of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Gastro One, Germantown, Tennessee, United States
🇨🇳
Local Institution, Taipei, Taiwan

Phase 2

Completed

Interventions: Drug: Daclatasvir
Drug: Asunaprevir
Drug: Pegylated interferon alfa-2a
Drug: Ribavirin

Locations: 🇺🇸
Scpmg/ Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸
University Of Pennsylvania, Philadelphia, Pennsylvania, United States

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.